Colorectal cancer

HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell

Retrieved on: 
Thursday, March 14, 2024
Liver, Liver failure, DOI, Cell death, Regeneration, Clinical professor, Colorectal cancer, Transplant, Gesellschaft mit beschränkter Haftung, Hepatectomy, Risk, Patient, MKK4, Mayo Clinic, Manuscript, Liver transplantation, Teaching hospital, Human, MAP, Liver regeneration, Hepatocyte, PHLF, Regenerative medicine, Safety, Hepatology, Liver disease, Dietary supplement

HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).

Key Points: 
  • HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).
  • “The positive results in terms of safety and tolerability confirm our intention to soon offer a drug that has the potential to revolutionize the treatment of severe liver diseases.
  • The data pave the way for further Phase II studies evaluating the efficacy of HRX-215 in humans,” emphasizes Dr. Wolfgang Albrecht, COO of HepaRegeniX.
  • Further, HRX-215 was also able to protect hepatocytes from cell death in a model for acute liver injury.

Fight Colorectal Cancer Unites Over 200 Advocates in Washington, D.C. for the 18th Annual Call-on Congress Event

Retrieved on: 
Tuesday, March 12, 2024
JAMA, Colorectal cancer, Congress, Disease, Caregiver, Incidence, Ageing, Exact sciences, Research, Woman, Statistics, Survivor, CDC, CRC, Large intestine, Dairy

WASHINGTON, D.C., March 12, 2024 (GLOBE NEWSWIRE) -- In a powerful display of unity, Fight Colorectal Cancer (Fight CRC) is hosting the 18th Annual Call-on Congress event, bringing together over 200 colorectal cancer survivors, caregivers, and loved ones.

Key Points: 
  • WASHINGTON, D.C., March 12, 2024 (GLOBE NEWSWIRE) -- In a powerful display of unity, Fight Colorectal Cancer (Fight CRC) is hosting the 18th Annual Call-on Congress event, bringing together over 200 colorectal cancer survivors, caregivers, and loved ones.
  • This landmark advocacy initiative aims to elevate personal stories and press for increased funding and support to combat colorectal cancer (CRC) .
  • Colorectal cancer, encompassing colon and rectal cancers, stands as the second-leading cause of cancer deaths for both men and women combined in the United States.
  • Encouraging Members of Congress to Champion Colorectal Cancer : Advocates will call on their representatives to become champions for colorectal cancer, actively working to transform the statistics surrounding the disease by joining the Colorectal Cancer Caucus.

ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors

Retrieved on: 
Saturday, April 6, 2024
Research, Women, FDA, Clinical Trials, Biotechnology, Pharmaceutical, Consumer, Health, Science, Oncology, Orbis, Urinary tract infection, Cardiac arrest, Stomatitis, Patient, Stroke, Lung cancer, University, Acute kidney injury, Neoplasm, Therapy, Anemia, Vomiting, Pleural effusion, Cellulitis, Shock (mechanics), Periodic breathing, Colorectal cancer, Abdominal pain, Safety, Immunohistochemistry, Fatigue, ADC, Daiichi Sankyo, Food, IHC, Sepsis, NSCLC, Appetite, Biliary tract, Constipation, NCCN, MD, Priority review, Fatality, Pneumonitis, HER2, ILD, Medication, Pneumonia, AstraZeneca, COVID-19, Biomarker, Diarrhea, Bleeding, MD Anderson Cancer Center, Nausea, Upper respiratory tract infection, Pharmaceutical industry

The first tumor agnostic approval of a HER2 directed therapy and ADC was based on efficacy data in 192 adult patients with previously treated unresectable or metastatic HER2 positive (IHC 3+) solid tumors who were enrolled in one of three multicenter phase 2 trials from the DESTINY clinical development program, including DESTINY-PanTumor02 , DESTINY-Lung01 or DESTINY-CRC02 .

Key Points: 
  • The first tumor agnostic approval of a HER2 directed therapy and ADC was based on efficacy data in 192 adult patients with previously treated unresectable or metastatic HER2 positive (IHC 3+) solid tumors who were enrolled in one of three multicenter phase 2 trials from the DESTINY clinical development program, including DESTINY-PanTumor02 , DESTINY-Lung01 or DESTINY-CRC02 .
  • In DESTINY-PanTumor02, efficacy was assessed in a subgroup of previously treated patients (n=111) with centrally or locally assessed HER2 positive (IHC 3+) solid tumors including either biliary tract, bladder, cervical, endometrial, ovarian, pancreatic or other tumors.
  • In DESTINY-Lung01, efficacy was assessed in a subgroup of patients (n=17) with centrally confirmed HER2 positive (IHC 3+) non-small cell lung cancer (NSCLC).
  • In DESTINY-CRC02, efficacy was assessed in the subgroup of patients (n=64) with centrally confirmed HER2 positive (IHC 3+) colorectal cancer.

Incendia Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research 2024

Retrieved on: 
Friday, April 5, 2024
Biotechnology, Pharmaceutical, Health, Oncology, TME, Orientation, Workflow, Tissue, Neoplasm, Research, Tumor microenvironment, CRC, Colorectal cancer

An end-to-end 3D spatial biology workflow, Alpenglow’s 3D I/O Pro™, was applied to colorectal cancer (CRC) tissues stained with nuclear and general protein fluorescent dyes to quantify lymphocyte density in tumor parenchyma and stroma and analyze collagen features, including orientation, within 3D regions of interest in the TME.

Key Points: 
  • An end-to-end 3D spatial biology workflow, Alpenglow’s 3D I/O Pro™, was applied to colorectal cancer (CRC) tissues stained with nuclear and general protein fluorescent dyes to quantify lymphocyte density in tumor parenchyma and stroma and analyze collagen features, including orientation, within 3D regions of interest in the TME.
  • The ratio of stromal to parenchymal lymphocytes (lymphocyte infiltration ratio) varied from 1.4 up to 9.1 in 3D volumes and 1 to 25 in 2D virtual sections taken throughout all 5 CRC samples.
  • Qualitatively, areas with perpendicular collagen had more lymphocyte infiltration into the tumor parenchyma than areas with parallel collagen orientation.
  • This work highlights how the 3D I/O Pro™ workflow can characterize tumors based on complex spatial relationships within the tumor microenvironment, and could have broad applicability in research and development of novel cancer therapies that target tumor fibrosis or other features of the TME.

Dxcover invited to present its CREATE-2 clinical trial for the early detection of colorectal cancer and advanced adenoma at the American Association for Cancer Research Annual Meeting 2024 in San Diego CA April 10

Retrieved on: 
Thursday, April 4, 2024
Oncology, Health, General Health, Clinical Trials, Research, Science, Biotechnology, Colonoscopy, Algorithm, Survival, Colorectal cancer, Patient, Cancer, Quality of life, FTIR, Machine learning, Blood, Fourier, Medical imaging

The CREATE-2 trial evaluates diagnostic accuracy for colorectal cancer and high-risk adenoma in patients undergoing a colonoscopy.

Key Points: 
  • The CREATE-2 trial evaluates diagnostic accuracy for colorectal cancer and high-risk adenoma in patients undergoing a colonoscopy.
  • The prospective observational study has two recruitment pathways, one in the US (targeting 1000 patients) and one in the UK (targeting 700 patients).
  • CREATE-2 intends to validate the previous feasibility study results from CREATE-1 which showed Dxcover’s ability to achieve accurate detection of pre-cancerous lesions and stage 1 colorectal cancer.
  • Dxcover’s Multi-Omic Spectral Analysis (MOSA-Dx™) enables analysis the full complement of signals within the blood to provide early detection of cancer.

OneOme Introduces RightMed Oncology: Empowering Clinicians to Personalize Treatment and Reduce Toxicity Risk with Pharmacogenomics

Retrieved on: 
Tuesday, April 2, 2024
FDA, Other Health, Practice Management, Pharmaceutical, Surgery, Managed Care, Oncology, Mental Health, Hospitals, Genetics, Clinical Trials, Biotechnology, Science, Other Science, Research, Health, Toxicity, DPYD, Irinotecan, Clinical professor, PMID, UGT1A1, Risk, Mayo Clinic, Mental health, Wastewater treatment, Cancer, Doctor of Philosophy, MD, Medicine, E pluribus unum, Safety, Patient safety, Pain management, DPD, Colorectal cancer, Vomiting, Clinical Pharmacogenetics Implementation Consortium, Pharmaceutical industry

The RightMed oncology portfolio empowers innovative health systems, oncology practices and prescribers to be as focused or comprehensive as their program requires.

Key Points: 
  • The RightMed oncology portfolio empowers innovative health systems, oncology practices and prescribers to be as focused or comprehensive as their program requires.
  • Using PGx can inform usage and dosage decisions for a wide range of chemotherapy and supportive care medications.
  • For more information about RightMed Oncology, please visit OneOmeInstitute.com/Oncology or reach out directly to discuss a PGx program for your health system.
  • OneOme aims to improve patient safety, reduce overall cost of care, and improve patients' health outcomes.

Oncoinvent Announces Changes to its Board of Directors and Formation of Scientific and Clinical Advisory Board

Retrieved on: 
Tuesday, April 2, 2024
Oncology, Health, Clinical Trials, Radiology, Pharmaceutical, Biotechnology, MSD, Ovarian cancer, Mirati Therapeutics, London Business School, University of Coimbra, GSK, BMS, Doctor of Philosophy, Therapy, Algeta, Colorectal cancer, International, Pharmacy, Radiopharmaceutical, Radium-223, Agios Pharmaceuticals, Amgen, Cubist Pharmaceuticals, Takeda Pharmaceutical Company, Bristol Myers Squibb, University, Private sector, The central science, Drug development, Sanofi, Psychiatry, BASF, Master of Science, M.B.A, Science, GE HealthCare, Pharmaceutical industry

“We are excited to welcome an internationally renowned group of industry leaders as new members of our Board of Directors.

Key Points: 
  • “We are excited to welcome an internationally renowned group of industry leaders as new members of our Board of Directors.
  • “We are also pleased to announce the formation of a Scientific and Clinical Advisory Board, consisting of our highly distinguished founders who are uniquely positioned to support Oncoinvent in our clinical programs.
  • Dr. O’Bryan-Tear has been an adviser to several US and European biotech companies and has held board positions at Fusion Pharmaceuticals and Clarity Pharmaceuticals.
  • In addition, Oncoinvent founding scientists Roy Larsen, Ph.D., and Øyvind Bruland, M.D., Ph.D., previously board members, will lead a newly established Scientific and Clinical Advisory Board.

GeneCentric Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
Monday, April 1, 2024
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Tempus, Survival, Colorectal cancer, Patient, RNA, MSI, FOLFIRINOX, PDAC, Medicine, Section 42, News, AACR, Microsatellite instability, Therapy, Cancer

GeneCentric Therapeutics , a company making precision medicine more precise through RNA-based diagnostics, today announced upcoming presentations at the American Association for Cancer Research Annual Meeting 2024 being held in San Diego, California from April 5-10.

Key Points: 
  • GeneCentric Therapeutics , a company making precision medicine more precise through RNA-based diagnostics, today announced upcoming presentations at the American Association for Cancer Research Annual Meeting 2024 being held in San Diego, California from April 5-10.
  • Presentations will include a poster describing a new colorectal cancer predictive response signature (MSS-PRS) that selects tumors not identified with conventional MSI testing but have molecular characteristics consistent with microsatellite instability, making them a potential target for immune checkpoint inhibition.
  • A second poster presentation describes ongoing clinical validation for PurISTSM, a novel RNA-expression test developed in collaboration with Tempus.
  • Details of the AACR presentations are as follows:
    Session: PO.CL01.01 – Diagnostic Biomarkers 1, Section 42
    The posters will be accessible under the News & Events section of the Company’s website following the conference.

Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer

Retrieved on: 
Monday, April 1, 2024
Research, Genetics, Clinical Trials, Biotechnology, Biometrics, Health, Pharmaceutical, Science, Oncology, NCI, Checkmate, Hematology, Immunotherapy, Cystectomy, Colorectal cancer, Patient, DNA, National Cancer Institute, Nature, Bladder cancer, MD, Medicine, NTRA, National Institutes of Health, Nivolumab, MRD, Safety, Bangladesh Technical Education Board, Multimedia, Recurrence, FDA, Transitional epithelium, PD-1, Medical imaging

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, and the Alliance for Clinical Trials in Oncology, which is part of the National Clinical Trials Network (NCTN) funded by the National Cancer Institute (NCI), part of National Institutes of Health, today announced the launch of Alliance A032103 ( MODERN ), a randomized, phase II/III, biomarker-integrated trial.

Key Points: 
  • Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, and the Alliance for Clinical Trials in Oncology, which is part of the National Clinical Trials Network (NCTN) funded by the National Cancer Institute (NCI), part of National Institutes of Health, today announced the launch of Alliance A032103 ( MODERN ), a randomized, phase II/III, biomarker-integrated trial.
  • Alliance A032103 (MODERN) will utilize Signatera™, Natera’s personalized and tumor-informed molecular residual disease (MRD) test, to help guide personalized treatment based on molecular status in patients diagnosed with muscle-invasive urothelial cancer (MIUC) after radical cystectomy.
  • Patients will be divided into two cohorts based on an initial assessment of MRD status.
  • “We are grateful to collaborate with the Alliance on this important study.”

The 3rd Annual V Foundation for Cancer Research Sonoma Epicurean Weekend Raises Over $3.4 Million

Retrieved on: 
Monday, March 25, 2024
Wine & Spirits, Philanthropy, Other Health, Health, Fund Raising, Other Philanthropy, Retail, Foundation, Oncology, Colorectal cancer, ESPN, SportsCenter, Lasseter Family Winery, Yoga, Travel, Research, Cancer, Food, Woman, Chef, Gala, Wine, Dionysus, Benovia Winery, Large intestine, Multimedia, Jim Valvano, NFL, Pharmaceutical industry

The 3rd annual V Foundation for Cancer Research Sonoma Epicurean weekend, held March 21-24 in Sonoma County’s renowned wine country, raised over $3.4 million.

Key Points: 
  • The 3rd annual V Foundation for Cancer Research Sonoma Epicurean weekend, held March 21-24 in Sonoma County’s renowned wine country, raised over $3.4 million.
  • View the full release here: https://www.businesswire.com/news/home/20240325542601/en/
    The V Foundation’s wine country events have raised nearly $170 million for cancer research over the last 25 years.
  • Since the V Foundation’s inception in 1993, the organization has awarded over $353 million in cancer research grants to world-class scientists at top cancer centers nationwide.
  • The 4th annual V Foundation Sonoma Epicurean weekend will take place March 20-23, 2025.